[
  {
    "ts": null,
    "headline": "More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.",
    "summary": "A triglyceride-cutting drug from  Ionis Pharmaceuticals  proved so effective in a trial reported this past weekend that the biotech’s shares jumped more than 30%.  Other news at the European Society of Cardiology Congress featured an  AstraZeneca  pill that the company thinks will become the best treatment for hard-to-control high blood pressure.  Merck offered a hint about a new cholesterol treatment, saying the long-awaited pill for lowering cholesterol achieved “meaningful” reductions in a Phase 3 trial.",
    "url": "https://finnhub.io/api/news?id=5bbb3bde79059b661fd16293170b24d210d814a41e6a015fef794889822003c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756854000,
      "headline": "More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off.",
      "id": 136612872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A triglyceride-cutting drug from  Ionis Pharmaceuticals  proved so effective in a trial reported this past weekend that the biotech’s shares jumped more than 30%.  Other news at the European Society of Cardiology Congress featured an  AstraZeneca  pill that the company thinks will become the best treatment for hard-to-control high blood pressure.  Merck offered a hint about a new cholesterol treatment, saying the long-awaited pill for lowering cholesterol achieved “meaningful” reductions in a Phase 3 trial.",
      "url": "https://finnhub.io/api/news?id=5bbb3bde79059b661fd16293170b24d210d814a41e6a015fef794889822003c2"
    }
  },
  {
    "ts": null,
    "headline": "This Merck Pill Promises Powerful Cholesterol Reduction Without Injections",
    "summary": "Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance). Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL cholesterol levels in the blood. It affects approximately 86 million adults in the U.S. and is a major risk driver for ASCVD, accounting for",
    "url": "https://finnhub.io/api/news?id=183d7d0b5f7885e9e2a04c9902131fd07b2175613c9f2daa340784b241dbbcc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756838177,
      "headline": "This Merck Pill Promises Powerful Cholesterol Reduction Without Injections",
      "id": 136613054,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc. (NYSE:MRK) on Tuesday shared topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance). Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL cholesterol levels in the blood. It affects approximately 86 million adults in the U.S. and is a major risk driver for ASCVD, accounting for",
      "url": "https://finnhub.io/api/news?id=183d7d0b5f7885e9e2a04c9902131fd07b2175613c9f2daa340784b241dbbcc4"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Announces Positive Results From Phase 3 CORALreef Lipids Trial",
    "summary": "Merck (MRK) recently announced positive topline results from the Phase 3 CORALreef Lipids trial, which contributed to the company's 7% share price rise over the last quarter. This trial confirmed the efficacy of enlicitide decanoate in significantly reducing LDL cholesterol levels. Simultaneously, the market has seen some volatility with tech sector declines and concerns over trade policies. In relation, Merck's advancements in cardiovascular treatment might have provided some counterbalance...",
    "url": "https://finnhub.io/api/news?id=f53e3e95e0a0ced2b4f4778d9f66d75b955492b6cc52c8e96a120aef79ca019a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756837475,
      "headline": "Merck (MRK) Announces Positive Results From Phase 3 CORALreef Lipids Trial",
      "id": 136613055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently announced positive topline results from the Phase 3 CORALreef Lipids trial, which contributed to the company's 7% share price rise over the last quarter. This trial confirmed the efficacy of enlicitide decanoate in significantly reducing LDL cholesterol levels. Simultaneously, the market has seen some volatility with tech sector declines and concerns over trade policies. In relation, Merck's advancements in cardiovascular treatment might have provided some counterbalance...",
      "url": "https://finnhub.io/api/news?id=f53e3e95e0a0ced2b4f4778d9f66d75b955492b6cc52c8e96a120aef79ca019a"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.",
    "url": "https://finnhub.io/api/news?id=bdf45b37ca1583ce90d60179cd23ab9971f221c9035ab3b22f707aecdfe71782",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756835820,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 136612960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors.",
      "url": "https://finnhub.io/api/news?id=bdf45b37ca1583ce90d60179cd23ab9971f221c9035ab3b22f707aecdfe71782"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=843719cfd6e1f18a6c44a8e811857df332421845b4a4bd3265d7192a3925e941",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756830840,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 136618660,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=843719cfd6e1f18a6c44a8e811857df332421845b4a4bd3265d7192a3925e941"
    }
  },
  {
    "ts": null,
    "headline": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
    "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
    "url": "https://finnhub.io/api/news?id=217ed689d8cfa7cb2bf09d2dc5295e9d583bbb676c3c402b7e32aa6a6abb4080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825800,
      "headline": "Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?",
      "id": 136613057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.",
      "url": "https://finnhub.io/api/news?id=217ed689d8cfa7cb2bf09d2dc5295e9d583bbb676c3c402b7e32aa6a6abb4080"
    }
  },
  {
    "ts": null,
    "headline": "Can Korlym Drive Corcept's Growth Through the Rest of 2025?",
    "summary": "CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.",
    "url": "https://finnhub.io/api/news?id=134d5e95cadd972fd9daa16b52156a2537944320d454668e4aff4171fdcb44ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756825080,
      "headline": "Can Korlym Drive Corcept's Growth Through the Rest of 2025?",
      "id": 136613058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.",
      "url": "https://finnhub.io/api/news?id=134d5e95cadd972fd9daa16b52156a2537944320d454668e4aff4171fdcb44ad"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Stock Underperforming the Nasdaq?",
    "summary": "Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=9862a39812bb2317d14fde86a66fa02a1b951c7c0ece925d708b2783254e38f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756822056,
      "headline": "Is Pfizer Stock Underperforming the Nasdaq?",
      "id": 136613059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=9862a39812bb2317d14fde86a66fa02a1b951c7c0ece925d708b2783254e38f1"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Verquvo Fails to Meet Primary Endpoint in Phase 3 Victor Trial",
    "summary": "Merck (MRK) said Saturday that its phase 3 Victor trial evaluating Verquvo, or vericiguat, in adult",
    "url": "https://finnhub.io/api/news?id=c797c11b70a82ac824b8f6ceff74682351dd5cfe3fa310ac026d91ae618b12cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756814430,
      "headline": "Merck's Verquvo Fails to Meet Primary Endpoint in Phase 3 Victor Trial",
      "id": 136604181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) said Saturday that its phase 3 Victor trial evaluating Verquvo, or vericiguat, in adult",
      "url": "https://finnhub.io/api/news?id=c797c11b70a82ac824b8f6ceff74682351dd5cfe3fa310ac026d91ae618b12cc"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study",
    "summary": "RAHWAY, N.J., September 02, 2025--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3",
    "url": "https://finnhub.io/api/news?id=6a6724718300f6317366c850b71d24bd90315469bcfe9c561fa7192eb7fc3e7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756813500,
      "headline": "Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study",
      "id": 136604182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 02, 2025--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3",
      "url": "https://finnhub.io/api/news?id=6a6724718300f6317366c850b71d24bd90315469bcfe9c561fa7192eb7fc3e7f"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference",
    "summary": "RAHWAY, N.J., September 02, 2025--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=e7ff04c41d8affa92d8b0b97f206a7d86d43cae59c4d40a1660ba78f3fccb280",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756812600,
      "headline": "Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference",
      "id": 136604183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 02, 2025--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=e7ff04c41d8affa92d8b0b97f206a7d86d43cae59c4d40a1660ba78f3fccb280"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028",
    "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals, vaccines, and animal health, continues to focus on innovation across oncology, cardiovascular, infectious diseases, and immunology. In 2025, the company […]",
    "url": "https://finnhub.io/api/news?id=3d85c5fe3173d4794c4ac4052234b92904bd51bd7f939f0938b53b4d9dac46a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756801643,
      "headline": "Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028",
      "id": 136604184,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Merck & Co., Inc. stands third among them. Merck & Co., Inc. (NYSE:MRK), a global leader in pharmaceuticals, vaccines, and animal health, continues to focus on innovation across oncology, cardiovascular, infectious diseases, and immunology. In 2025, the company […]",
      "url": "https://finnhub.io/api/news?id=3d85c5fe3173d4794c4ac4052234b92904bd51bd7f939f0938b53b4d9dac46a1"
    }
  }
]